Search Results - "SEIBOLD, James"

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study by Coghlan, J Gerry, Denton, Christopher P, Grünig, Ekkehard, Bonderman, Diana, Distler, Oliver, Khanna, Dinesh, Müller-Ladner, Ulf, Pope, Janet E, Vonk, Madelon C, Doelberg, Martin, Chadha-Boreham, Harbajan, Heinzl, Harald, Rosenberg, Daniel M, McLaughlin, Vallerie V, Seibold, James R

“…Earlier detection of pulmonary arterial hypertension (PAH), a leading cause of death in systemic sclerosis (SSc), facilitates earlier treatment. The objective…”
Get more information

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group by Khanna, Dinesh, Mittoo, Shikha, Aggarwal, Rohit, Proudman, Susanna M, Dalbeth, Nicola, Matteson, Eric L, Brown, Kevin, Flaherty, Kevin, Wells, Athol U, Seibold, James R, Strand, Vibeke

“…Interstitial lung disease (ILD) is common in connective tissue disease (CTD) and is the leading cause of mortality. Investigators have used certain outcome…”
Get full text

Response to: 'Correspondence on 'Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial'' by Bredemeier by Seibold, James R, Kohlbrenner, Veronika, Alves, Margarida, Distler, Oliver

Get more information

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial by Khanna, Dinesh, Albera, Carlo, Fischer, Aryeh, Khalidi, Nader, Raghu, Ganesh, Chung, Lorinda, Chen, Dan, Schiopu, Elena, Tagliaferri, Margit, Seibold, James R, Gorina, Eduard

“…Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number of clinical features and pathogenic mechanisms with idiopathic pulmonary…”
Get full text

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial by Seibold, James R, Maher, Toby M, Highland, Kristin B, Assassi, Shervin, Azuma, Arata, Hummers, Laura Kathleen, Costabel, Ulrich, von Wangenheim, Ute, Kohlbrenner, Veronika, Gahlemann, Martina, Alves, Margarida, Distler, Oliver

“…To characterise the safety and tolerability of nintedanib and the dose adjustments used to manage adverse events in patients with systemic sclerosis-associated…”
Get more information

Nintedanib in Patients With Autoimmune Disease–Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial by Matteson, Eric L., Kelly, Clive, Distler, Jörg H. W., Hoffmann‐Vold, Anna‐Maria, Seibold, James R., Mittoo, Shikha, Dellaripa, Paul F., Aringer, Martin, Pope, Janet, Distler, Oliver, James, Alexandra, Schlenker‐Herceg, Rozsa, Stowasser, Susanne, Quaresma, Manuel, Flaherty, Kevin R.

“…Objective To analyze the efficacy and safety of nintedanib in patients with fibrosing autoimmune disease–related interstitial lung diseases (ILDs) with a…”
Get full text

Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis by Khanna, Dinesh, Furst, Daniel E., Clements, Philip J., Allanore, Yannick, Baron, Murray, Czirjak, Lazlo, Distler, Oliver, Foeldvari, Ivan, Kuwana, Masataka, Matucci-Cerinic, Marco, Mayes, Maureen, Medsger, Thomas, Merkel, Peter A., Pope, Janet E., Seibold, James R., Steen, Virginia, Stevens, Wendy, Denton, Christopher P.

“…The modified Rodnan skin score (mRSS) is a measure of skin thickness and is used as a primary or secondary outcome measure in clinical trials of systemic…”
Get full text

Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence by Vonk, Madelon C., Smith, Vanessa, Sfikakis, Petros P., Cutolo, Maurizio, del Galdo, Francesco, Seibold, James R.

“…Many therapies have been investigated for systemic sclerosis-associated interstitial lung disease (SSc-ILD), including immunosuppressive therapies,…”
Get full text

Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis by Nagaraja, Vivek, Matucci‐Cerinic, Marco, Furst, Daniel E., Kuwana, Masataka, Allanore, Yannick, Denton, Christopher P., Raghu, Ganesh, Mclaughlin, Vallerie, Rao, Panduranga S., Seibold, James R., Pauling, John D., Whitfield, Michael L., Khanna, Dinesh

“…Systemic sclerosis (SSc) is an autoimmune rheumatic disease with heterogeneous clinical manifestations and a variable course in which the severity of the…”
Get full text

STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease by Khanna, Dinesh, Tashkin, Donald P, Wells, Athol U, Seibold, James R, Wax, Stephen, Vazquez-Mateo, Cristina, Fleuranceau-Morel, Patricia, Damian, Doris, Denton, Christopher P

“…To investigate the effects of abituzumab in systemic sclerosis-associated interstitial lung disease (SSc-ILD). STRATUS was a phase II, double-blind,…”
Get full text

Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames) by Seibold, James R., Wigley, Fredrick M.

Get full text

Survival in Systemic Sclerosis With Pulmonary Arterial Hypertension Has Not Improved in the Modern Era by Rubenfire, Melvyn, MD, Huffman, Mark D., MD, MPH, Krishnan, Sangeetha, MS, Seibold, James R., MD, Schiopu, Elena, MD, McLaughlin, Vallerie V., MD, FCCP

“…Background The impact of modern therapy on survival in pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc) is not clear. We sought…”
Get full text

A deeper look at skin scoring in scleroderma – surrogate, outcome, neither or both? by Seibold, James R

Get full text

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial by Matucci-Cerinic, Marco, Denton, Christopher P, Furst, Daniel E, Mayes, Maureen D, Hsu, Vivien M, Carpentier, Patrick, Wigley, Fredrick M, Black, Carol M, Fessler, Barri J, Merkel, Peter A, Pope, Janet E, Sweiss, Nadera J, Doyle, Mittie K, Hellmich, Bernhard, Medsger, Jr, Thomas A, Morganti, Adele, Kramer, Fabrice, Korn, Joseph H, Seibold, James R

“…Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc) and are a cause of disease-related morbidity. In an earlier trial,…”
Get more information

Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials by Humbert, Marc, Singh, Manjit, Furst, Daniel E, Khanna, Dinesh, Seibold, James R

“…There are proven successful approaches to clinical trial design in pulmonary arterial hypertension (PAH), which in turn have led to the licensing of a number…”
Get full text

Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis by Rabquer, Bradley J, Tsou, Pei-Suen, Hou, Yong, Thirunavukkarasu, Eshwar, Haines, 3rd, G Kenneth, Impens, Ann J, Phillips, Kristine, Kahaleh, Bashar, Seibold, James R, Koch, Alisa E

“…Systemic sclerosis (SSc) is characterized by fibrosis and microvascular abnormalities including dysregulated angiogenesis. Chemokines, in addition to their…”
Get full text

Cyclophosphamide versus Placebo in Scleroderma Lung Disease by Tashkin, Donald P, Elashoff, Robert, Clements, Philip J, Goldin, Jonathan, Roth, Michael D, Furst, Daniel E, Arriola, Edgar, Silver, Richard, Strange, Charlie, Bolster, Marcy, Seibold, James R, Riley, David J, Hsu, Vivien M, Varga, John, Schraufnagel, Dean E, Theodore, Arthur, Simms, Robert, Wise, Robert, Wigley, Fredrick, White, Barbara, Steen, Virginia, Read, Charles, Mayes, Maureen, Parsley, Ed, Mubarak, Kamal, Connolly, M. Kari, Golden, Jeffrey, Olman, Mitchell, Fessler, Barri, Rothfield, Naomi, Metersky, Mark

“…Interstitial lung disease is a common complication of systemic sclerosis, but there is no widely accepted treatment. In this randomized, placebo-controlled…”
Get full text

Assessment of pulmonary arterial hypertension in patients with systemic sclerosis: comparison of noninvasive tests with results of right-heart catheterization by HSU, Vivien M, MOREYRA, Abel E, WILSON, Alan C, SHINNAR, Meir, SHINDLER, Daniel M, WILSON, Julianne E, DESAI, Ami, SEIBOLD, James R

“…OBJECTIVE: Pulmonary hypertension (PH) is an ominous complication in patients with scleroderma (systemic sclerosis, SSc). We compared noninvasive assessment of…”
Get full text

Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort by Mihai, Carina, Antic, Milos, Dobrota, Rucsandra, Bonderman, Diana, Chadha-Boreham, Harbajan, Coghlan, John Gerry, Denton, Christopher P, Doelberg, Martin, Grünig, Ekkehard, Khanna, Dinesh, McLaughlin, Vallerie V, Müller-Ladner, Ulf, Pope, Janet E, Rosenberg, Daniel M, Seibold, James R, Vonk, Madelon C, Distler, Oliver

“…Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc). In this longitudinal study, we aimed to identify factors associated…”
Get more information

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study by Visovatti, Scott H, Distler, Oliver, Coghlan, J Gerry, Denton, Christopher P, Grünig, Ekkehard, Bonderman, Diana, Müller-Ladner, Ulf, Pope, Janet E, Vonk, Madelon C, Seibold, James R, Torres-Martin, Juan-Vicente, Doelberg, Martin, Chadha-Boreham, Harbajan, Rosenberg, Daniel M, McLaughlin, Vallerie V, Khanna, Dinesh

“…Patients with mean pulmonary artery pressures (mPAP) of 21 to 24 mm Hg have a so-called borderline elevation of mPAP (BoPAP)--a condition thought to represent…”
Get full text